  | Sabbe, M., Vervier, J., GUISSARD, F., PAULUS, V., SANCHEZ, C., Bougard, N., Frix, A.-N., Schleich, F., & Louis, R. (2024). Relationship between T2 biomarkers and clinical remission in severe T2 high asthmatics after 12 months of treatment with omalizumab, mepolizumab and benralizumab. European Respiratory Journal 64(suppl 68): PA4815 Published: Sep 2024, 4815. doi:10.1183/13993003.congress-2024.pa4815 |
 | Zahraei, H. N., Schleich, F., Louis, G., Gerday, S., SABBE, M., Bougard, N., GUISSARD, F., PAULUS, V., Henket, M., Pétré, B., Donneau, A.-F., & Louis, R. (2024). Evidence for two clusters among non-eosinophilic asthmatics. Annals of Allergy, Asthma and Immunology. doi:10.1016/j.anai.2024.03.012  Peer Reviewed verified by ORBi |
 | Schleich, F., Moermans, C., Gerday, S., ZIANT, S., Louis, G., Bougard, N., PAULUS, V., GUISSARD, F., Henket, M., Bachert, C., & Louis, R. (October 2023). Patients With Asthma Only Sensitized to Staphylococcus aureus Enterotoxins Have More Exacerbations, Airflow Limitation, and Higher Levels of Sputum IL-5 and IgE. Journal of Allergy and Clinical Immunology: In Practice, 11 (10), 3055-3061.e4. doi:10.1016/j.jaip.2023.05.043 Peer Reviewed verified by ORBi Dataset: 10.1016/j.jaip.2023.05.043 |
 | Sabbe, M., Schleich, F., Bougard, N., Moermans, C., Henquet, M., GUISSARD, F., Sanschez, C., PAULUS, V., & Louis, R. (2023). Sputum cell counts and FeNO levels in patients treated with anti-IgE and anti-IL-5 /IL-5R: Evidence for a dissociation between sputum eosinophil counts and FeNO levels. European Respiratory Journal 62(suppl 67): PA989 Published: Sep 2023, 989. doi:10.1183/13993003.congress-2023.pa989 Peer reviewed |
 | Louis, R., Louis, G., Bougard, N., LOUIS, S., ZIANT, S., Pétré, B., Schleich, F., Bury, T., & Delvaux, M. (May 2023). La dyspnée «sine materia». Revue Médicale de Liège, 78 (5-6), 351 - 355. Editorial Reviewed verified by ORBi |
 | Schleich, F., Bougard, N., Moermans, C., Sabbe, M., & Louis, R. (April 2023). Cytokine-targeted therapies for asthma and COPD. European Respiratory Review: an Official Journal of the European Respiratory Society, 32 (168). doi:10.1183/16000617.0193-2022 Peer reviewed Dataset: 10.1183/16000617.0193-2022 |
 | Schleich, F., Graff, S., Bougard, N., Frix, A.-N., Peerboom, S., Demarche, S., GUISSARD, F., PAULUS, V., Henket, M., CALMES, D., Moermans, C., & Louis, R. (May 2022). L’asthme bronchique en pratique clinique : des phénotypes inflammatoires au traitement personnalisé. Revue Médicale de Liège, 77 (5-6), 289-294. Editorial Reviewed verified by ORBi |
 | Louis, R., Bougard, N., Louis, G., Pétré, B., & Schleich, F. (October 2021). Le médicament du mois. Combinaison fixe mométasone, indacatérol, glycopyrronium pour le traitement de l’asthme sévère : Enerzair® Breezhaler®. Revue Médicale de Liège, 76 (10), 768-772. Editorial Reviewed verified by ORBi |
 | Louis, R., Bougard, N., GUISSARD, F., PAULUS, V., HENKET, M., & Schleich, F. (February 2020). Bronchodilation Test with Inhaled Salbutamol Versus Bronchial Methacholine Challenge to Make an Asthma Diagnosis: Do They Provide the Same Information? Journal of Allergy and Clinical Immunology: In Practice, 8 (2), 618-625.e8. doi:10.1016/j.jaip.2019.09.007 Peer Reviewed verified by ORBi |
 | Bougard, N., Nekoee Zahraei, H., SCHLEICH, F., GUISSARD, F., PAULUS, V., Donneau, A.-F., & Louis, R. (2020). Assessment of diagnostic accuracy of lung function indices and FeNO for a positive methacholine challenge. Biochemical Pharmacology. doi:10.1016/j.bcp.2020.113981 Peer Reviewed verified by ORBi |